BICYCLE THERAPEUTICS TO PRESENT PRECLINICAL DATA ON LEAD MOLECULE BT1718 AT THE
AACR-NCI-EORTC INTERNATIONAL CANCER CONFERENCE
CAMBRIDGE, U.K., and CAMBRIDGE, Mass., Oct. 26, 2017 – Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that the company will present data describing the mechanism of action of BT1718, Bicycle’s lead molecule, which is being developed to target cancers of high unmet need including triple negative breast cancer and non small cell lung cancer. The data will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Philadelphia, Pennsylvania from October 26 – 30, 2017.
Details for the poster presentation, which will be given by Gavin Bennett, Ph.D., Bicycle’s Head of Preclinical Development, are as follows:
Title: The mechanism of action of BT1718, a novel small-molecule drug conjugate for the treatment of solid tumors expressing MT1-MMP
Session: PO.B20 – Therapeutic Agents: Other Topics
Poster #: B135
Date & Time: Sunday, October 29, 2017, 12:30 – 4:00 p.m. ET
About Bicycle Therapeutics
Bicycle Therapeutics is developing a unique class of chemically synthesized medicines based on its proprietary bicyclic peptide (Bicycle®) product platform to address therapeutic needs unreachable with existing treatment modalities. Bicycle’s internal focus is in oncology, where the company is developing targeted cytotoxics (Bicycle Toxin Conjugates), targeted innate immune activators and T-cell modulators for cancers of high unmet medical need. Bicycles’ small size and exquisite targeting delivers rapid tumour penetration and retention while clearance rates and routes can be tuned to minimise exposure of healthy tissue and bystander toxicities. The company’s lead program, BT1718, is rapidly advancing towards the clinic in collaboration with Cancer Research, UK. The company’s unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis. Bicycle has its headquarters in Cambridge, U.K., with many key functions and members of its leadership team located in the biotech hub of Boston, Mass. For more information, visit www.bicycletherapeutics.com or follow us on Twitter at @Bicycle_tx.
Ten Bridge Communications (U.S.)